"Gold rush" on high-value niche antibiotics will take a toll; Datamonitor

Just weeks following the publication of a new report by independent market analyst Datamonitor highlighting the fact that effective drug treatments for key bacterial pathogens are being missed by pharmaceutical R&D portfolios, the World Health Organization has also drawn attention to the absence of options for hard-to-treat bacterial infections. Datamonitor's research suggests that there are also substantial gaps in the types of infection that pharmaceutical companies are seeking to cover.

Focus on "superbugs"

This is a shot in the foot for the companies involved, given that their focus on "superbugs" is largely a result of attempting to capitalize on the few remaining portions of the antibiotics market that offer any real promise of substantial returns: problematic infections for which there are limited treatment options.